Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Colonoscopy | Research

A Phase 2 evaluation of a new flavored peg and sulfate solution compared to an over-the-counter laxative, peg and sports drink bowel preparation combination

Authors: Gregory Wiener, Peter Winkle, John D. McGowan, Mark vB. Cleveland, Jack A. Di Palma

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Acceptability and tolerance of bowel preparation is critical to overcome patient hesitancy in undergoing colon cancer screening and surveillance colonoscopy. To improve patient experience, a new sports drink-flavored bowel preparation containing polyethylene glycol (PEG) and sulfate salts (FPSS) was developed to provide a similar experience to a commonly used but not United States Food and Drug Administration (FDA) approved PEG and sports drink bowel preparation (PEG-SD), while also achieving improved cleansing efficacy.

Methods

This FPSS preparation, approved by the FDA in June 2023, was evaluated in a non-randomized Phase 2 study in which 40 patients requiring colonoscopy were prepared with FPSS and 20 with PEG-SD.

Results

Overall cleansing success was high with FPSS based on unblinded local endoscopist assessment (93%) and blinded central reading (97%), exceeding PEG-SD which achieved success rates of 84% (local read), 74% and 68% (blinded central reads). Similar differences favoring FPSS were seen for excellent preparations and cleansing success by colon segment as rated by local endoscopists. Both preparations were well-tolerated, with 93% of FPSS patients rating their preparation as Tolerable to Very Easy to consume, compared to 100% of PEG-SD. Patients who had previously taken a preparation for colonoscopy found FPSS and PEG-SD better than their prior preparation (73% and 70%, respectively) and nearly all would request their assigned study preparation again in the future. About two thirds of FPSS patients agreed that the preparation tasted similar to a sports drink.

Conclusion

The new sports drink-like flavored preparation compares favorably to PEG-SD for bowel cleansing efficacy while achieving similar patient satisfaction. The study was registered at www.​clinicaltrials.​gov (NCT03328507) on 01/11/2017.
Literature
1.
go back to reference Gu P, Lew D, Oh SJ, Vipani A, Ko J, Hsu K, Mirakhor E, Pattisapu V, Bullen T, Fuller G, Spiegel BMR, Almario CV. Comparing the real-world effectiveness of competing Colonoscopy preparations: results of a prospective trial. Am J Gastroenterol. 2019;114(2):305–14.CrossRefPubMedPubMedCentral Gu P, Lew D, Oh SJ, Vipani A, Ko J, Hsu K, Mirakhor E, Pattisapu V, Bullen T, Fuller G, Spiegel BMR, Almario CV. Comparing the real-world effectiveness of competing Colonoscopy preparations: results of a prospective trial. Am J Gastroenterol. 2019;114(2):305–14.CrossRefPubMedPubMedCentral
2.
go back to reference Vemulapalli KC, Lahr RE, Rex DK. 2021 Patient Perceptions Regarding Colonoscopy Experience. J Clin Gastroenterol 2023;57(4):400–403. Vemulapalli KC, Lahr RE, Rex DK. 2021 Patient Perceptions Regarding Colonoscopy Experience. J Clin Gastroenterol 2023;57(4):400–403.
3.
go back to reference Matro R, et al. Randomised clinical trial: polyethylene glycol 3350 with sports drink vs. polyethylene glycol with Electrolyte Solution as Purgatives for Colonoscopy – the incidence of Hyponatraemia. Aliment Pharmacol Ther. 2014;40(6):610–19.CrossRefPubMed Matro R, et al. Randomised clinical trial: polyethylene glycol 3350 with sports drink vs. polyethylene glycol with Electrolyte Solution as Purgatives for Colonoscopy – the incidence of Hyponatraemia. Aliment Pharmacol Ther. 2014;40(6):610–19.CrossRefPubMed
4.
go back to reference Walker M, Bass R, Hague K, Cleveland MV. A Formulation Development Study of BLI4900, a novel flavor enhanced Bowel Preparation for Colonoscopy. Gastrointestinal Endoscopy, Volume 95, Issue 6, AB67. Walker M, Bass R, Hague K, Cleveland MV. A Formulation Development Study of BLI4900, a novel flavor enhanced Bowel Preparation for Colonoscopy. Gastrointestinal Endoscopy, Volume 95, Issue 6, AB67.
5.
go back to reference Schoenfeld P. Safety of MiraLAX/Gatorade Bowel Preparation has not been established in appropriately-designed studies. Clin Gastroenterol Hepatol. 2013;11(5):582.CrossRefPubMedPubMedCentral Schoenfeld P. Safety of MiraLAX/Gatorade Bowel Preparation has not been established in appropriately-designed studies. Clin Gastroenterol Hepatol. 2013;11(5):582.CrossRefPubMedPubMedCentral
6.
go back to reference Lewis J, Schoenfeld P. Severe hyponatremia and Miralax-Gatorade Bowel Preparation. Am J Gastro. 2011;106(2):5582–3. Lewis J, Schoenfeld P. Severe hyponatremia and Miralax-Gatorade Bowel Preparation. Am J Gastro. 2011;106(2):5582–3.
7.
go back to reference Di Palma JA, Bhandari R, Cleveland MV, Mishkin DS, Tesoriero J, Hall S, McGowan J. A safety and efficacy comparison of a New Sulfate-based Tablet Bowel Preparation Versus a PEG and Ascorbate Comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319–28.CrossRefPubMed Di Palma JA, Bhandari R, Cleveland MV, Mishkin DS, Tesoriero J, Hall S, McGowan J. A safety and efficacy comparison of a New Sulfate-based Tablet Bowel Preparation Versus a PEG and Ascorbate Comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319–28.CrossRefPubMed
Metadata
Title
A Phase 2 evaluation of a new flavored peg and sulfate solution compared to an over-the-counter laxative, peg and sports drink bowel preparation combination
Authors
Gregory Wiener
Peter Winkle
John D. McGowan
Mark vB. Cleveland
Jack A. Di Palma
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Colonoscopy
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03069-8

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.